• Quantum Biopharma posted a net loss of USD 13.75 million, widening from USD 8.74 million a year earlier; loss per share narrowed to USD 3.06 from USD 3.53.
• Operating loss narrowed to USD 2.97 million from USD 3.4 million, while loss on fair value changes in derivative liabilities and warrant liability climbed to USD 6.95 million from USD 3.11 million.
• Unrealized loss on change in fair value of digital assets increased to USD 1.24 million from USD 718,827; digital assets rose to USD 5.47 million from USD 2.21 million at Dec. 31, 2025.
• Cash and cash equivalents rose to USD 4.34 million from USD 1.91 million at Dec. 31, 2025; cash used in operating activities narrowed to USD 1.67 million from USD 4.26 million.
• Subsequent to March 31, 2026, USD 1.42 million of gross proceeds were raised under at-the-market sales; 94,408 shares were issued April 16, 2026 and 84,702 shares were issued April 28, 2026 on convertible debenture conversions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-001738), on May 06, 2026, and is solely responsible for the information contained therein.